17 Feb 2021
A North East bioscience centre has been selected to deliver cutting-edge training in cell and gene therapy and vaccine manufacturing.
The move, which further cements the Tees Valley’s growing reputation as a global hub for the bioscience sector, follows last months' news a Covid vaccine will be manufactured on Teesside.
Alongside RoslinCT in Edinburgh and the University of Birmingham, the NHC is one of three training centres that will deliver high impact courses as part of the growing ATSTN programme.
The NHC, which is based at the university’s Darlington campus at Central Park, opened in 2019 to deliver research, education and collaboration to help grow the UK’s bioscience sector.
ATSTN is a nationwide skills development programme driven by industry and coordinated by the Cell and Gene Therapy Catapult, funded by £4.7m as part of the Government’s commitment to expand the country's expertise in advanced therapies and vaccine manufacturing.
A core aim of the ATSTN is to develop a coordinated network of centres to deliver on-site courses including those using virtual reality, providing learners with the hands-on expertise and experience to succeed in the advanced therapies and vaccine manufacturing sector.